Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesSomnomed Ltd

Somnomed Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.29 AUD -0.02 ( 6.45%)
Last update at 2026-11-05T23:34:00Z
VOLUME
2876
Market Cap
68.13M

Momentum Score

…

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. The company offers SomnoDent, such as SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, herbst advance, and SomnoDent Fusion for the treatment of obstructive sleep apnea. It also provides SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.29
Low
0.32
High
52 Week Price Range
0.23
Low
0.81
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Somnomed Ltd designs and supplies custom oral appliances for obstructive sleep apnea and snoring, distributed through a network of dental partners across Australia, the US and Europe. Long-term growth may be supported by rising OSA diagnosis, increasing acceptance of mandibular advancement devices, geographic expansion and ongoing product development. Investors may find the company attractive for its focused market position and recurring device and service revenue streams.

Principal risks include competition from CPAP and alternative therapies, changes to reimbursement and regulation, reliance on dental channels and execution risk in international expansion.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.31
Dividend Yield
-
Revenue TTM
114.53M
Revenue Per Share
0.53
Gross Profit TTM
70.02M
Debt / Equity
0.12
ROE
-5.65%
Net Debt
-11.73M
ROCE
1.89%
Diluted EPS TTM
-0.01

Insight News

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -0.46M -0.76M -11.27M -7.05M -3.50M
Net income -2.65M -3.46M -12.24M -8.00M -4.44M
Selling general administrative 46.21M 20.19M 18.01M 14.15M 13.81M
Selling and marketing expenses - 22.91M 26.18M 24.49M 19.74M
Gross profit 60.91M 66.73M 55.13M 45.77M 39.15M
Reconciled depreciation 5.49M - 5.78M 5.12M 3.94M
Ebit 0.98M -0.31M -8.10M -4.42M -3.41M
Ebitda 6.46M 1.58M -2.33M 0.70M 0.52M
Depreciation and amortization 5.49M 1.89M 5.78M 5.12M 3.94M
Operating income 0.98M 3.62M -8.33M -4.07M -4.13M
Other operating expenses 113.56M 107.88M 99.98M 87.69M 76.71M
Interest expense 0.46M 0.40M 3.17M 2.63M 0.38M
Tax provision 2.19M 2.69M 0.97M 0.82M 0.93M
Interest income 0.09M - 0.03M 0.00M 0.00M
Net interest income -0.38M - -3.14M -2.62M -0.38M
Extraordinary items - - 0.00M -0.13M -0.01M
Income tax expense 2.19M 2.69M 0.97M 0.82M 0.93M
Total revenue 114.53M 111.49M 91.65M 83.62M 72.58M
Total operating expenses 59.94M 63.11M 57.60M 49.84M 43.28M
Cost of revenue 53.62M 44.76M 36.52M 37.85M 33.43M
Total other income expense net -1.43M -4.38M -2.94M -2.97M 0.64M
Discontinued operations - - - -0.13M -0.01M
Net income from continuing ops -2.65M - -12.24M -7.87M -4.43M
Net income applicable to common shares - -3.46M -12.24M -8.00M -4.44M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 75.00M 80.97M 69.80M 62.49M 58.09M
Intangible assets 15.83M 1.56M - 12.48M 9.41M
Other current assets 2.78M 7.23M 4.43M 0.32M 0.27M
Total liab 27.60M 34.58M 24.78M 40.09M 30.31M
Total stockholder equity 47.40M 46.39M 45.02M 22.40M 27.79M
Deferred long term liab - - - 9.67M 6.62M
Other current liab 14.96M 6.41M 4.05M 3.20M 11.18M
Common stock 112.20M 119.96M 110.23M 74.27M 74.27M
Capital stock 112.20M - - 74.27M 74.27M
Retained earnings -80.64M -77.94M -74.54M -62.29M -54.30M
Other liab - - - 0.79M 1.18M
Good will 6.54M 7.05M 6.34M 6.49M 6.04M
Other assets - - - 3.25M 9.83M
Cash 17.18M 17.29M 16.18M 11.96M 15.64M
Cash and equivalents - - - 11.96M 15.64M
Total current liabilities 23.27M 28.58M 19.94M 18.36M 23.77M
Current deferred revenue 0.04M - 0.18M 0.00M -6.66M
Net debt -11.73M -9.27M -9.46M 11.55M -3.63M
Short term debt 2.25M 2.83M 2.60M 2.57M 6.66M
Short long term debt 0.10M - - 0.31M 4.88M
Short long term debt total 5.46M 8.03M 6.72M 23.51M 12.01M
Other stockholder equity - - 9.33M -21.76M -29.76M
Property plant equipment - - - 12.73M 9.12M
Total current assets 38.95M 43.14M 35.14M 27.50M 30.32M
Net tangible assets - - - 13.10M 18.96M
Net receivables 11.63M 11.19M 8.24M 8.71M 8.93M
Long term debt 0.31M - - 16.36M 2.01M
Inventory 7.36M 7.43M 6.29M 4.10M 3.09M
Accounts payable 6.01M 19.34M 13.11M 12.59M 12.59M
Accumulated other comprehensive income 15.85M 4.37M - 10.43M 7.81M
Non currrent assets other - 15.26M 13.97M -22.04M -17.94M
Non current assets total 36.05M 37.83M 34.67M 35.00M 27.78M
Capital lease obligations 5.04M - - 6.84M 5.12M
Long term debt total - - - 20.94M 5.35M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - -5.34M -6.41M 0.32M
Change to liabilities - - - -1.88M 2.34M
Total cashflows from investing activities -5.74M -3.98M -5.34M -6.41M -8.47M
Net borrowings 1.67M - -16.79M 6.61M 2.09M
Total cash from financing activities -1.47M -3.38M 16.68M 6.61M 2.09M
Change to operating activities - - - 0.03M 0.70M
Net income -2.65M -3.46M -12.24M -8.00M -4.44M
Change in cash -0.11M 1.11M 4.22M -3.69M -5.47M
Begin period cash flow 17.29M 16.18M 11.96M 15.64M 21.11M
End period cash flow 17.18M 17.29M 16.18M 11.96M 15.64M
Total cash from operating activities 8.28M 7.78M -6.33M -3.88M 1.86M
Issuance of capital stock - - 38.08M - -
Depreciation 5.49M 5.74M 6.80M 3.97M 3.38M
Other cashflows from investing activities - -1.56M -3.95M 0.00M 0.32M
Change to inventory -0.78M -0.69M -2.20M -1.01M -0.76M
Change to account receivables 2.85M -4.17M -1.43M 0.37M -0.37M
Sale purchase of stock -0.02M 0.00M -2.07M 0.00M 0.00M
Other cashflows from financing activities 1.98M -0.04M -2.54M 12.95M 2.09M
Change to netincome - - - 1.68M 0.46M
Capital expenditures 3.26M 2.42M 1.39M 6.41M 8.79M
Change in working capital 0.26M -4.23M -1.07M -0.64M -1.13M
Stock based compensation - 1.95M 0.08M 1.04M 1.19M
Other non cash items 5.18M 7.78M 0.10M 0.15M 2.92M
Free cash flow 5.02M 5.36M -7.72M -10.29M -6.93M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
SOM
Somnomed Ltd		 -0.02
6.45%		 0.29 - 0.18 0.59 1.39 0.47 10.66
COH
Cochlear Ltd		 1.03
0.67%		 155.47 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 -0.03
2.29%		 1.28 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 -0.36
4.21%		 8.20 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.08
1.73%		 4.55 - 9.97 9.59 7.17 6.76 15.37

Profile*

Somnomed Ltd

SomnoMed Limited, together with its subsidiaries, produce and sells devices for the oral treatment of sleep related disorders in the Asia Pacific region, North America, and Europe. The company offers SomnoDent, such as SomnoDent Avant, SomnoDent Classic, SomnoDent Flex, herbst advance, and SomnoDent Fusion for the treatment of obstructive sleep apnea. It also provides SomMorning Repositioner, a product designed to help return patient's mandible back to its pre-treatment centric position; SomnoBrux splint, a custom fit, acrylic splint for patient's upper teeth designed to protect teeth from grinding and scraping during Bruxism; and SomTabs, which are cleaning tablets to clean oral appliances. SomnoMed Limited was incorporated in 1987 and is headquartered in Crows Nest, Australia.

20 Clarke Street, Crows Nest, NSW, Australia, 2065

61 2 9467 0400

https://somnomed.com/au/

Name Title Year Born
Mr. Neil Verdal-Austin B.Com., C.A. Global CEO, MD & Director NA
Mr. Hervé Fiévet Global Chief Financial Officer NA
Mr. Mark Harding VP of Global Marketing NA
Mr. Matthew Conlon Exec. VP Sales & Marketing - North America NA
Mr. Marco Van Kleef VP of Marketing & Sales - Europe NA
Dr. Jagdeep Bijwadia Chief Medical Officer NA
Mr. Terence A. Flitcroft B.Com., B.Comm., C.A., CA, SF FIN Company Sec. 1959
Dr. Peter Spencer MBA Ph.D., MAICD Gen. Mang. of Operations 1956
Mr. Christopher Bedford VP of Global Production and Product Devel. NA
Mr. Mark Harding Vice President of Global Marketing NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…